Both companies are top-notch. But which stock is trading at a more attractive valuation relative to its long-term prospects? Read More...
Motley Fool
Is It Too Late to Buy Novavax Stock?
Investors looking for exposure to the coronavirus vaccine market may naturally gravitate toward the two leaders in this segment, Moderna and Pfizer. One of those is biotech Novavax (NASDAQ: NVAX), a company whose shares are up by an impressive 5,630% since January 2020. Despite this amazing performance, Novavax has yet to market its potential COVID-19 vaccine, NVX-CoV2373.
Add Comment